How does T3X0's PS Ratio compare to its peers?

T3X0 is expensive based on its Price-To-Sales Ratio (12.8x) compared to the peer average (9.8x).

How does T3X0's PS Ratio compare vs other companies in the DE Biotechs Industry?

T3X0 is expensive based on its Price-To-Sales Ratio (12.8x) compared to the European Biotechs industry average (8.1x).

What is T3X0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate T3X0's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of T3X0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

T3X0 (€14.7) is trading below our estimate of [[fair value]] (€28.36)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

T3X0 Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. More details

T3X0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 48.2% below our estimate of its fair value

Earnings are forecast to grow 38.32% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Telix Pharmaceuticals Limited Competitors

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€937.6m

2invest

XTRA:2INV

€67.8m

Heidelberg Pharma

XTRA:HPHA

€113.7m

Price History & Performance

Summary of share price highs, lows and changes for Telix Pharmaceuticals
Historical stock prices
Current Share Price	AU$14.70
52 Week High	AU$15.90
52 Week Low	AU$14.63
Beta	2.41
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.67%

Recent updates

Shareholder Returns

	T3X0	DE Biotechs	DE Market
7D	-2.0%	2.3%	0.3%
1Y	n/a	-12.8%	6.9%

Return vs Industry: Insufficient data to determine how T3X0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how T3X0 performed against the German Market.

Price Volatility

Is T3X0's price volatile compared to industry and market?
T3X0 volatility
T3X0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: T3X0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine T3X0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	423	Chris Behrenbruch	telixpharma.com

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.

Telix Pharmaceuticals Limited Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
T3X0 fundamental statistics
Market cap	€4.94b
Earnings (TTM)	€29.42m
Revenue (TTM)	€386.16m

167.9x

P/E Ratio

12.8x

P/S Ratio

Is T3X0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T3X0 income statement (TTM)
Revenue	AU$645.68m
Cost of Revenue	AU$240.33m
Gross Profit	AU$405.35m
Other Expenses	AU$356.16m
Earnings	AU$49.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.15
Gross Margin	62.78%
Net Profit Margin	7.62%
Debt/Equity Ratio	2.9%

How did T3X0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 13:40
End of Day Share Price	2024/12/30 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telix Pharmaceuticals Limited is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter
Andrew Paine	CLSA

Telix Pharmaceuticals DB:T3X0 Stock Report